Tuberculosis in Children vs. Adults: What Are The Key Differences?
"A new study from Abidjan reveals significant contrasts in how TB manifests and affects children compared to adults, crucial for improving diagnosis and treatment strategies."
Tuberculosis (TB) remains a significant global health challenge, particularly in developing countries. While often thought of as an adult disease, TB affects children substantially, accounting for an estimated 5% to 20% of all TB cases worldwide. Understanding how TB presents differently in children versus adults is crucial for effective diagnosis, treatment, and public health management.
A recent study conducted in Abidjan, Côte d'Ivoire, sheds light on the specific differences between childhood TB (TBE) and adult TB (TBA). This retrospective analysis, which examined data from thousands of TB cases, highlights key variations in epidemiology, clinical presentation, and treatment outcomes. The findings offer valuable insights for healthcare professionals and policymakers aiming to improve TB control strategies.
This article explores the salient points of the Abidjan study, providing a comprehensive overview of how TB uniquely impacts children. By understanding these differences, we can advocate for more targeted interventions, ultimately reducing the burden of this disease on vulnerable populations.
Tracking the Global Burden
The CDC publishes tuberculosis data on multiple topics to track progress toward elimination. The World Health Organization provides country-reported data and estimates of TB burden for its Global tuberculosis report. Research using the Global Burden of Disease Study 2021 has assessed TB incidence and mortality among children and adolescents under 15 from 1990 to 2021, including projected burden through a Bayesian age-period-cohort model.
Diagnosis Depends on Context
Mycobacterial culture remains the most sensitive method for microbiological confirmation of TB in children, but many children are diagnosed clinically despite negative microbiological testing, making culture an imperfect reference standard. CDC guidelines recommend the TB skin test for children younger than five years, although some experts use TB blood tests in this age group. Diagnostic strategies also vary with TB prevalence: one analysis found that at lower prevalence, only the TB-Speed two-step approach might be cost-effective, while limited access to microbiological testing continues to hinder childhood case detection.
A Developing Field
The history of tuberculosis care has been shaped by gradual advances in recognizing infection, confirming disease, and developing effective treatment. Pediatric TB has required distinct attention because disease can present differently in children and may be difficult to confirm microbiologically. The modern approach therefore reflects an evolving understanding of how age, disease severity, and diagnostic limitations influence care.
Key Differences in TB Presentation: Children vs. Adults
The study in Abidjan meticulously compared 2,617 cases of childhood TB (TBE) with 36,648 cases of adult TB (TBA), uncovering notable distinctions:
- HIV Co-infection: Children with TB had a significantly lower rate of HIV co-infection (24.5%) compared to adults (44%).
- Type of TB: The study revealed differences in the types of TB prevalent in children versus adults. Pulmonary TB (TB affecting the lungs) was common in both groups, but children were more likely to have smear-negative pulmonary TB.
- Location of TB: Extrapulmonary TB (TB occurring outside the lungs) also showed variations in location. Lymph node involvement was more frequent among children (30.1%) than adults (12.1%), while pleural TB (TB affecting the lining of the lungs) was more common in adults (51.3%) compared to children (26.2%).
- Treatment Outcomes: Children experienced better treatment outcomes compared to adults. The rate of treatment failure or death was significantly lower in children (1.9%) than in adults (3.9%).
Shorter and Better-Suited Treatments
Recent reviews from the Asia-Pacific region describe ongoing efforts to improve TB detection, treatment, and prevention in children and young people. A major treatment landmark is a shortened four-month regimen for nonsevere TB, alongside an all-oral regimen for multidrug-resistant TB. A 2026 scoping review found that shorter regimens were generally associated with higher completion rates, although evidence about cure rates remained limited; research priorities also include safer regimens and better screening, diagnosis, and prevention.
Why Pediatric TB Is Missed
Childhood TB often follows the initial infection after a shorter interval than in adults: the interval is often weeks to months in small children, compared with years to decades in adults. Diagnosis is especially difficult because pediatric disease is frequently paucibacillary and suitable samples can be hard to obtain. These challenges, together with controversies around diagnosis and prevention, can contribute to delayed diagnosis, inadequate linkage to care, and limited access to effective treatment, particularly in children under five.
Age Changes the Risk Profile
Children require special considerations when clinicians test and treat both inactive TB, also called latent TB infection, and active TB disease. According to the CDC, once infected with TB germs, children, especially those younger than five years, are more likely to develop active TB disease. These age-related differences help explain why symptoms, diagnostic decisions, treatment approaches, and public health strategies cannot simply be transferred from adults to children.
Tailoring TB Strategies for Children: A Call to Action
The Abidjan study provides critical insights into the unique characteristics of tuberculosis in children. By recognizing these differences in presentation, HIV co-infection rates, and treatment outcomes, healthcare systems can develop more targeted and effective strategies to combat TB in this vulnerable population. This includes focusing on early diagnosis, tailored treatment regimens, and preventive measures, ultimately reducing the burden of TB and improving the health and well-being of children worldwide.
Shorter Therapy for Selected Cases
Evidence discussed in the New England Journal of Medicine supports shorter treatment for selected children with nonsevere TB. The findings apply only to nonsevere disease, but most cases of TB in children initially manifest as nonsevere disease with a low bacillary burden. This creates an opportunity to use differentiated treatment while recognizing that the approach should not automatically be extended to severe TB.
Protecting the Youngest Children
A 2025 analysis reported significant age-related trends in TB incidence and mortality, with children under five accounting for more than half of new cases and 75% of TB-related deaths. Drug-resistant TB in children is described as a growing global health concern, requiring continued attention to its epidemiology, incidence, prevalence, and mortality. Future work also includes projecting disease trends through 2045 for drug-susceptible and multidrug-resistant TB among children and adolescents.
Beyond Individual Patients
Childhood TB remains a major concern despite global progress in TB prevention and control. Its persistence is linked to a complex natural history, varied clinical presentations, and frequent diagnostic difficulties. The impact can extend from families to communities and societies, and in high-prevalence settings children with TB may contribute to ongoing transmission.
Consequences Across the Life Course
The socioeconomic impact of TB in childhood and adolescence can be understood through a life-course lens, particularly because TB may be severe and relatively chronic while mitigation measures are inadequate. Case reports from a tertiary care hospital illustrate diagnostic and therapeutic challenges across different pediatric ages and disease spectrums. Longitudinal research has also examined how early-life TB affects child and lung health through childhood, including whether preexisting lung impairment predisposes children to TB.